Topical glaucoma medications: Clinical implications for the ocular surface

Research output: Contribution to journal › Review › Research › peer-review

Standard

Topical glaucoma medications : Clinical implications for the ocular surface. / Fineide, Fredrik; Lagali, Neil; Adil, Muhammed Yasin; Arita, Reiko; Kolko, Miriam; Vehof, Jelle; Utheim, Tor P.

In: Ocular Surface, Vol. 26, 2022, p. 19-49.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Fineide, F, Lagali, N, Adil, MY, Arita, R, Kolko, M, Vehof, J & Utheim, TP 2022, 'Topical glaucoma medications: Clinical implications for the ocular surface', Ocular Surface, vol. 26, pp. 19-49. https://doi.org/10.1016/j.jtos.2022.07.007

APA

Fineide, F., Lagali, N., Adil, M. Y., Arita, R., Kolko, M., Vehof, J., & Utheim, T. P. (2022). Topical glaucoma medications: Clinical implications for the ocular surface. Ocular Surface, 26, 19-49. https://doi.org/10.1016/j.jtos.2022.07.007

Vancouver

Fineide F, Lagali N, Adil MY, Arita R, Kolko M, Vehof J et al. Topical glaucoma medications: Clinical implications for the ocular surface. Ocular Surface. 2022;26:19-49. https://doi.org/10.1016/j.jtos.2022.07.007

Author

Fineide, Fredrik ; Lagali, Neil ; Adil, Muhammed Yasin ; Arita, Reiko ; Kolko, Miriam ; Vehof, Jelle ; Utheim, Tor P. / Topical glaucoma medications : Clinical implications for the ocular surface. In: Ocular Surface. 2022 ; Vol. 26. pp. 19-49.

Bibtex

@article{de7ce55661f24e3699fa5e7fa4035fc8,
title = "Topical glaucoma medications: Clinical implications for the ocular surface",
abstract = "Glaucoma is a leading cause of irreversible blindness. The use of topical eye drops to reduce intraocular pressure remains the mainstay treatment. These eye drops frequently contain preservatives designed to ensure sterility of the compound. A growing number of clinical and experimental studies report the detrimental effects of not only these preservatives but also the active pharmaceutical compounds on the ocular surface, with resultant tear film instability and dry eye disease. Herein, we critically appraise the published literature exploring the effects of preservatives and pharmaceutical compounds on the ocular surface.",
keywords = "Dry eye disease, Eyedrops, Glaucoma, Meibomian gland dysfunction, Topical medications",
author = "Fredrik Fineide and Neil Lagali and Adil, {Muhammed Yasin} and Reiko Arita and Miriam Kolko and Jelle Vehof and Utheim, {Tor P.}",
note = "Funding Information: Tor Paaske Utheim is co-founder and co-owner of The Norwegian dry eye clinic and the Clinic of eye health, Oslo, Norway, which delivers talks for and/or receives financial support from the following: ABIGO, Alcon, Allergan, AMWO, Bausc'h&Lomb, Bayer, European school for advanced studies in ophthalmology, InnZ Medical, Medilens Nordic, Medistim, Novartis, Santen, Specsavers, Shire Pharmaceuticals and Thea Laboratories. He has served on the global scientific advisory board for Novartis and Alcon as well as the European advisory board for Shire Pharmaceuticals. Utheim is the Norwegian Global Ambassador for Tear Film and Ocular Surface Society (TFOS), a Board Member of the International Ocular Surface Society, an International Member of the Japanese Lid and Meibomian gland working group (LIME), a Consultant at the Norwegian Association for the Blind and Partially Sighted, the President of the Oslo Society of ophthalmology, and the Editor-in-Chief of Oftalmolog, an eye journal distributed to all eye doctors in the Nordic region since 1980. Besides publishing articles of presumed interest to our readers, Oftalmolog publishes advertisements from pharmaceutical companies, companies selling ophthalmological equipment, and associations organizing conferences and events in ophthalmology. For more information, visit: oftalmolog.com . ",
year = "2022",
doi = "10.1016/j.jtos.2022.07.007",
language = "English",
volume = "26",
pages = "19--49",
journal = "The Ocular Surface",
issn = "1542-0124",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Topical glaucoma medications

T2 - Clinical implications for the ocular surface

AU - Fineide, Fredrik

AU - Lagali, Neil

AU - Adil, Muhammed Yasin

AU - Arita, Reiko

AU - Kolko, Miriam

AU - Vehof, Jelle

AU - Utheim, Tor P.

N1 - Funding Information: Tor Paaske Utheim is co-founder and co-owner of The Norwegian dry eye clinic and the Clinic of eye health, Oslo, Norway, which delivers talks for and/or receives financial support from the following: ABIGO, Alcon, Allergan, AMWO, Bausc'h&Lomb, Bayer, European school for advanced studies in ophthalmology, InnZ Medical, Medilens Nordic, Medistim, Novartis, Santen, Specsavers, Shire Pharmaceuticals and Thea Laboratories. He has served on the global scientific advisory board for Novartis and Alcon as well as the European advisory board for Shire Pharmaceuticals. Utheim is the Norwegian Global Ambassador for Tear Film and Ocular Surface Society (TFOS), a Board Member of the International Ocular Surface Society, an International Member of the Japanese Lid and Meibomian gland working group (LIME), a Consultant at the Norwegian Association for the Blind and Partially Sighted, the President of the Oslo Society of ophthalmology, and the Editor-in-Chief of Oftalmolog, an eye journal distributed to all eye doctors in the Nordic region since 1980. Besides publishing articles of presumed interest to our readers, Oftalmolog publishes advertisements from pharmaceutical companies, companies selling ophthalmological equipment, and associations organizing conferences and events in ophthalmology. For more information, visit: oftalmolog.com .

PY - 2022

Y1 - 2022

N2 - Glaucoma is a leading cause of irreversible blindness. The use of topical eye drops to reduce intraocular pressure remains the mainstay treatment. These eye drops frequently contain preservatives designed to ensure sterility of the compound. A growing number of clinical and experimental studies report the detrimental effects of not only these preservatives but also the active pharmaceutical compounds on the ocular surface, with resultant tear film instability and dry eye disease. Herein, we critically appraise the published literature exploring the effects of preservatives and pharmaceutical compounds on the ocular surface.

AB - Glaucoma is a leading cause of irreversible blindness. The use of topical eye drops to reduce intraocular pressure remains the mainstay treatment. These eye drops frequently contain preservatives designed to ensure sterility of the compound. A growing number of clinical and experimental studies report the detrimental effects of not only these preservatives but also the active pharmaceutical compounds on the ocular surface, with resultant tear film instability and dry eye disease. Herein, we critically appraise the published literature exploring the effects of preservatives and pharmaceutical compounds on the ocular surface.

KW - Dry eye disease

KW - Eyedrops

KW - Glaucoma

KW - Meibomian gland dysfunction

KW - Topical medications

U2 - 10.1016/j.jtos.2022.07.007

DO - 10.1016/j.jtos.2022.07.007

M3 - Review

C2 - 35921942

AN - SCOPUS:85135711997

VL - 26

SP - 19

EP - 49

JO - The Ocular Surface

JF - The Ocular Surface

SN - 1542-0124

ER -

ID: 318205833